U.S. FDA approved pembrolizumab for NSCLC as single-agent for adjuvant and in combination with chemo for neoadjuvant settings – American Association for Cancer Research

American Association for Cancer Research recently shared on its Twitter page:

“Today, the U.S. FDA approved the immune checkpoint inhibitor pembrolizumab in combination with chemotherapy before surgery and continuation as a single-agent treatment after surgery for some patients with non-small cell lung cancer.”